23 May 2013
Keywords: Merck Serono, Merck KGaA, Ablynx, Nanobodies, Osteoarthritis
Article | 09 November 2011
Merck Serono, a division of Germany’s Merck KGaA (MRK: DE) has entered into a third agreement with Ablynx ( ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
9 November 2011
© 2013 thepharmaletter.com